Early-life treatment of antiserotonin antibodies alters sensitivity to serotonin receptors, nociceptive stimulus and serotonin metabolism in adult rats

International Journal of Developmental Neuroscience

Volumn 28, Issue 4, 2010, Pages 317-324

  Bhanja, Shravani ^a   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

CNS 5 HT development; Dopamine; Hyperserotoninemia; Immunization against autism spectrum disorders; Nucleus raphe; Pain; Tremor

Indexed keywords

5 METHOXY N,N DIMETHYLTRYPTAMINE; ANTIBODY; DOPAMINE; NORADRENALIN; RADIOACTIVE IODINE; SEROTONIN; SEROTONIN ANTIBODY; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ADULTHOOD; ANIMAL EXPERIMENT; ARTICLE; AUTISM; BEHAVIOR CHANGE; BODY WEIGHT; BRAIN REGION; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DORSAL RAPHE NUCLEUS; FEMALE; GRAY MATTER; MALE; NEWBORN; NOCICEPTIVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; SEROTONIN BLOOD LEVEL; SEROTONIN METABOLISM; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES; DOPAMINE; FEMALE; MALE; NEURONS; NOREPINEPHRINE; NUCLEUS ACCUMBENS; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SEROTONIN; SUBSTANTIA NIGRA;

ANIMALIA; ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 77952831489     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2010.02.007     Document Type: Article

References (70)

1. Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Intl. Rev. Neurobiol. 2007, 78:133-164.
2. Alreja M., Mutalik P., Nayar U., Manchanda S.K. The formalin test: tonic pain model in the primate. Pain 1984, 20:97-105.
3. Anderson G.M., Horne W.C., Chatterjee D., Cohen D.J. Hyperserotoninemia of autism. Ann. N. Y. Acad. Sci. 1990, 600:331-340.
4. Ansorge M.S., Zhou M., Lira A., Hen R., Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004, 306:879-881.
5. Azmitia E.C., Davila Frankfurt M., Whitaker-Azmitia P.M., Zhou F.C. Plasticity of fetal and adult CNS serotoninergic neurons: role of growth-regulatory factors. Ann. N. Y. Acad. Sci. 2001, 600:343-365.
6. Boylan C.B., Blue M.E., Hohmann C.F. Modeling early cortical serotonergic deficits in autism. Behav. Brain Res. 2007, 176:94-108.
7. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr. Res. 1995, 14:187-202.
8. Brimijoin S., Lennon V.A. Selective destruction of preganglionic sympathetic nerves by antibodies to acetylcholinesterase. J. Neural. Transm. (Suppl.) 1991, 34:139-145.
9. Brodkin E.S. BALB/c mice: low sociability and other phenotypes that may be relevant to autism. Behav. Brain Res. 2007, 176:53-65.
10. Butkevich I.P., Mikhailenko V.A., Leont'eva M.N. Sequelae of prenatal serotonin depletion and stress on pain sensitivity in rats. Neurosci. Behav. Physiol. 2005, 35:925-930.
11. Carneiro A.M., Cook E.H., Murphy D.L., Blakely R.D. Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J. Clin. Invest. 2008, 118:1544-1552.
12. Chugani D.C. Role of altered brain serotonin mechanisms in autism. Mol. Psychiatr. 2002, 7(Suppl 2):S16-S17.
13. Chugani D.C., Muzik O., Behen M., Rothermel R., Janisse J.J., Lee J., Chugani H.T. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann. Neurol. 1999, 45:287-295.
14. Costa M., Geffen L.B., Rush A., Bridges D., Blessing W.W., Heath J.W. Immune lesions of central noradrenergic neurons produced by antibodies to dopamine-β-hydroxylase. Brain Res. 1979, 173:65-78.
15. De Vitry F., Hamon M., Catelon L., Dubois M., Thibault J. Serotonin initiates and autoamplifies its own synthesis during mouse central nervous system development. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:8629-8633.
16. Durig J., Hornung J.P. Neonatal serotonin depletion affects developing and mature mouse cortical neurons. Neuroreport 2000, 11:833-837.
17. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence. J. Psychiatric Res. 1983, 17:319-334.
18. Ferrari M.D., Saxena P.R. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 2002, 13:151-165.
19. Fragoso-Loyo H., Cabiedes J., Orozco-Narváez A., Dávila-Maldonado L., Atisha-Fregoso Y., Diamond B., Llorente L., Sánchez-Guerrero J. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS ONE 2008, 3:e3347.
20. Gaspar P., Cases O., Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nature Rev. Neurosci. 2003, 4:1002-1012.
21. Grahame-Smith D.G. Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br. J. Pharmacol. 1971, 43:856-864.
22. Guhathakurta S., Ghosh S., Sinha S., Chatterjee A., Ahmed S., Chowdhury S.R., Gangopadhyay P.K., Ghosh S., Singh M., Usha R. Serotonin transporter promoter variants: analysis in Indian autistic and control population. Brain Res. 2006, 1092:28-35.
23. Guhathakurta S., Sinha S., Ghosh S., Chatterjee A., Ahmed S., Gangopadhyay P.K., Usha R. Population-based association study and contrasting linkage disequilibrium pattern reveal genetic association of SLC6A4 with autism in the Indian population from West Bengal. Brain Res. 2008, 1240:12-21.
24. Guhathakurta S., Singh A.S., Sinha S., Chatterjee A., Ahmed S., Ghosh S., Usha R. Analysis of serotonin receptor 2A gene (HTR2A): association study with autism spectrum disorder in the Indian population and investigation of the gene expression in peripheral blood leukocytes. Neurochem. Int. 2009, 55:754-759.
25. Halford J.C., Harrold J.A., Lawton C.L., Blundell J.E. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets 2005, 6:201-213.
26. Hamon M., Bourgoin S. Endogenous levels of 5-HT, tryptophan and 5-hydroxyindoleacetic acid (5-HIAA) in the brain of developing rats. Biology of Serotoninergic Transmission 1982, 197-220. John Wiley and Sons, England. N.N. Osborne (Ed.).
27. Heath M.J.S., Hen R. Genetic insights into serotonin function. Curr. Opin. Neurobiol. 1995, 5:997-999.
28. 7 receptor research. Trends Pharmacol. Sci. 2004, 25:481-486.
29. Hoshino Y., Yamamoto T., Kaneko M., Tachibana R., Watanabe M., Ono Y., Kumashiro H. Blood serotonin and free tryptophan concentration in autistic children. Neuropsychobiology 1984, 11:22-27.
30. Jacobs B.L. An animal model for studying central serotoninergic synapses. Life Sci. 1976, 19:77-86.
31. Jagota A., Kalyani D. Daily serotonin rhythms in rat brain during postnatal development and aging. Biogerontology 2008, 9:229-234.
32. 3A and 5-HTT knock-out male mice. Pain 2007, 130:235-248.
33. Lauder J.M. Hormonal and humoral influences on brain development. Psychoneuroendocrinology 1983, 8:121-155.
34. Lauder J.M. Ontogeny of the serotoninergic system in the rat: serotonin as a developmental signal. Ann. N.Y. Acad. Sci. 1990, 600:297-314.
35. Lauder J.M. Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci. 1993, 16:233-240.
36. Leboyer M., Philippe A., Bouvard M., Guilloud-Bataille M., Bondoux D., Tabuteau F., Feingold J., Mouren-Simeoni M.C., Launay J.M. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol. Psychiatry 1999, 45:158-163.
37. Martino D., Giovannoni G. Anti-basal ganglia antibodies and their relevance to movement disorders. Curr. Opin. Neurol. 2004, 17:425-432.
38. Mc Conahey P.J., Dixon F.J. A method of trace iodination of proteins for immunologic studies. Int. Arch. Allergy Appl. Immunol. 1966, 29:185-189.
39. Mehta H., Thomas B., Mohanakumar K.P. Effects of p-chlorophenylalanine on striatal acetylcholinesterase activity and on biogenic amine levels in raphe, tuberculum olfactorium and caudate-putamen during physostigmine-induced tremor in rats. Neurosci. Lett. 2001, 299:105-108.
40. Mehta H., Saravanan K.S., Mohanakumar K.P. Serotonin synthesis inhibition in olivo-cerebellar system attenuates harmaline-induced tremor in Swiss albino mice. Behav. Brain Res. 2003, 145:31-36.
41. Mehta H., Haobam R., Usha R., Mohanakumar K.P. Evidence for the involvement of central serotoninergic mechanisms in cholinergic tremor induced by tacrine. Behav. Brain Res. 2005, 163:227-236.
42. Mirmiran M.E., Swaab D.F. Influence of drugs on brain neurotransmitters and behavioral states during development. Dev. Pharmacol. Ther. 1987, 10:377-384.
43. Mitra N., Mohanakumar K.P., Ganguly D.K. Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res. Bull. 1992, 28:355-364.
44. Miyazaki K., Narita N., Narita M. Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. Int. J. Dev. Neurosci. 2005, 23:287-297.
45. Mohanakumar K.P., Ganguly D.K. Tremorogenesis by LON-954 [N-carbamoyl-2-(2,6-dichlorophenyl) acetamidine hydrochloride]: evidence for the involvement of 5-hydroxytryptamine. Brain Res. Bull. 1989, 22:191-195.
46. Mohanakumar K.P., Mitra N., Ganguly D.K. Tremorogenesis by physostigmine is unrelated to acetylcholinesterase inhibition: evidence for serotoninergic involvement. Neurosci. Lett. 1990, 120:91-93.
47. Mohanakumar K.P., Mohanty S., Ganguly D.K. Neonatal treatment with 5-HT antiserum alters 5-HT metabolism and function in rats. Neuroreport 1995, 7:238-240.
48. Mohanty S., Steinbusch H.W.M., Ganguly D.K., Mohanakumar K.P. Behavioural and neurochemical alterations following intracerebroventricular administration of antiserotonin antibodies in adult balb/c mice. J. Chem. Neroanat. 1998, 14:141-149.
49. Moratalla R., Sanchez-Franco F., Del Rio J. Long-term hyperplasia in rats induced by neonatal administration of vasopressin antiserum. Life Sci. 1985, 38:109-115.
50. Narita N., Kato M., Tazoe M., Miyazaki K., Narita M., Okado N. Increased monoamine concentration in the brain and blood of fetal thalidomide-and valproic acid-exposed rat: putative animal models for autism. Pediatr. Res. 2002, 52:576-579.
51. A receptor binding in panic disorder. J. Neurosci. 2004, 24:589-591.
52. Oades R.D. The role of the serotonin system in ADHD: treatment implications. Expert Rev. Neurother. 2007, 7:1357-1374.
53. Ouchterlony O., Nilsson L.A. Immunodiffusion and immunoelectrophoresis. Handbook of Experimental Immunology 1986, vol. 1:32.1-32.50. Blackwell, Oxford, UK. 4th edition.
54. Parker C.W. Radiolabelling of proteins. Methods Enzymology 1990, vol. 162:723-726. Academic Press, New York.
55. Piven J., Tsai G., Nehme E., Coyle J.T., Folstein S.E. Platelet serotonin, a possible marker for familial autism. J. Autism Dev. Disord. 1991, 21:51-59.
56. Sarkar S., Thomas B., Muralikrishnan D., Mohanakumar K.P. Effects of serotoninergic drugs on tremor induced by physostigmine. Behav. Brain Res. 2000, 109:187-193.
57. Singh V.K., Singh E.A., Warren R.P. Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol. Psychiat. 1997, 41:753-755.
58. Sodhi M.S., Sanders-Bush E. Serotonin and disorders of brain development. Int. Rev. Neurobiol. 2004, 59:111-174.
59. Steinbusch H.W., Verhofstad A.A., Joosten H.W. Localization of serotonin in the central nervous system by immunohistochemistry: description of specific and sensitive technique and some applications. Neuroscience 1978, 3:811-819.
60. Szczudlik A. The role of serotonin in the pathophysiology of migraine. Neurol. Neurochem. Pol. Suppl. 1992, 2:14-27.
61. Tsujino N., Nakatani Y., Seki Y., Nakasato A., Nakamura M., Sugawara M., Arita H. Abnormality of circadian rhythm accompanied by an increase in frontal cortex serotonin in animal model of autism. Neurosci. Res. 2007, 57:289-295.
62. Vataeva L.A., Kudrin V.S., Vershinina E.A., Mosin V.M., Tiul'kova E.I., Otellin V.A. Maternal para-chlorophenylalanine exposure modifies central monoamines and behaviors in the adult offspring. Brain Res. 2008, 1234:1-7.
63. Vogt M., Teunissen C.E., Iacobaeus E., Heijnen P., Breij E., Olsson T., Brundin L., Killestein J., Dijkstra C.D. CSF anti-myelin antibodies are related to MR measures of disease activity in multiple sclerosis. Neurol. Neurosurg. Psychiatr. 2008, 80:1110-1115.
64. Neuropharmacology of serotonin. Ann. N.Y. Acad. Sci. 1990, 600:717.
65. Whitaker-Azmitia P.M. Serotonin and brain development: role in human developmental diseases. Brain Res. Bull. 2001, 56:479-485.
66. Whitaker-Azmitia P.M. Behavioral and cellular consequences of increased serotonin during development. Int. J. Dev. Neurosci. 2005, 23:75-83.
67. Yuwiler A., Shih J.C., Chen C.H., Ritvo E.R., Hanna G., Ellison G.W., King B.H. Hyperserotoninemia and antiserotonin antibodies in autism and other disorders. J. Autism Dev. Disord. 1992, 22:33-45.
68. Zaichenko A.P., Malinovskaia N.B., Pinchuk M.P. Various reactions of humoral and cellular immunity in Parkinson's disease. Vrach Delo 1981, 1(January):94-97.
69. Zeiglgansberger W. Central control of nociception. Handbook of Physiology 1986, 581-645. Williams and Wilkins, Baltimore. V.B. Montcastle, E.F. Bloom, S.R. Geiger (Eds.).
70. Zhou F.C., Sari Y., Powrozek T.A. Fetal alcohol exposure reduces serotonin innervation and compromises development of the forebrain along the serotonergic pathway. Alcohol Clin. Exper. Res. 2006, 29:141-149.